NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/24/2026 15:50
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,435.54 mln
Float185 mln
Earnings Date11/09/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-2.97
Likely reliable
Relative Strength
93
/ 100
Top performer
Debt / Equity
0.15
Very low leverage
ROE
-64.97
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Ocular Therapeutix is a US-based company focused on treating eye diseases through its proprietary dissolvable gel technology. Its flagship product, DEXTENZA, is already on the market and helps manage eye inflammation, pain, and allergic reactions. The company is also advancing a pipeline of next-generation treatments for serious conditions such as macular degeneration, diabetic eye disease, and glaucoma, with several programs in late-stage clinical testing. Founded in 2006 and based in Bedford, Massachusetts, Ocular Therapeutix works with partner AffaMed Therapeutics to expand the reach of select products into additional markets.
